



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 61429

Title: Triple osimertinib administrations followed by chemotherapy for advanced lung adenocarcinoma : A case report

Reviewer's code: 05467040

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: China

Manuscript submission date: 2020-12-07

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2020-12-23 03:23

Reviewer performed review: 2020-12-23 09:15

Review time: 5 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

The original findings of this manuscript is the first report of re-challenge and tri-challenge of osimertinib successfully applied through multiple re-sensitization chemotherapy on an NSCLC patient. It is a new phenomena that were found through experiments in this study. All the ctDNA results confirmed the treatment in this study. The quality and importance of this manuscript is quite good. The conclusions do appropriately summarize the data that this study provided and they offer a useful reference for retreatment with osimertinib. Although the manuscript had offered the certification of Language Editing, there are still typos there, such as "disappered" and "slightly". I suggested the authors could pay more attention to the English writing. Another minor revision is there are several times in the process using ctDNA sequencing without any details about the detection. The author should describe they had used the right detection method to monitor the genomics status of the patient. In brief, this study could impact clinical practice based on precise genetic testing.



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 61429

Title: Triple osimertinib administrations followed by chemotherapy for advanced lung adenocarcinoma : A case report

Reviewer's code: 00045333

Position: Peer Reviewer

Academic degree: PhD

Professional title: Associate Professor

Reviewer's Country/Territory: South Korea

Author's Country/Territory: China

Manuscript submission date: 2020-12-07

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2020-12-23 23:42

Reviewer performed review: 2020-12-24 02:29

Review time: 2 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Review report on manuscript World Journal of Clinical Cases 61429 entitled “Triple osimertinib administrations followed by chemotherapy of advanced lung adenocarcinoma patient with acquired resistance improved patient survival: A case report” This study is to report the efficacy of multi-use of osimertinib after resistance acquired for patients with metastatic lung adenocarcinoma. My comments and suggestions are as below. Please note the detail sample in which the 2nd and the 3rd ctDNA analysis was performed. ‘The patient refused the third gene detection’ sentence of the last line of page 4, ‘the third gene detection’ is considered to be a count of errors. Please reveal the changes of CA19-9 level in the figure 3. Please mark the references correctly in each sentence of the discussion which mentioned on the previous studies. Please correct misspellings throughout the manuscript and the wrong unit. Ex) u/mL, effectsis, and CEA(ug/ml).